Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-10-26 Governance Information
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 投资者关系管理制度' which translates to 'Investor Relations Management System of Yunnan Biological Valley Pharmaceutical Co., Ltd.' It is a detailed policy document outlining the company's investor relations management principles, objectives, responsibilities, and procedures. It includes references to regulatory compliance, communication with investors, disclosure principles, and internal controls. There is no financial data, earnings information, or report content such as annual or quarterly financial statements. It is not an announcement of a report publication but a governance-related document describing internal rules and practices related to investor relations. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-10-26 Chinese
董事、监事薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 董事、监事薪酬管理制度' which translates to 'Yunnan Biological Valley Pharmaceutical Co., Ltd. Directors and Supervisors Remuneration Management System.' It details the remuneration policies, principles, management structure, salary standards, payment, and adjustment mechanisms for the company's board members and supervisors. It includes procedural and governance aspects related to compensation but does not contain financial statements, earnings data, or audit information. It is a detailed report on compensation policies and governance related to remuneration. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document is substantive and not merely an announcement or summary, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is DEF 14A with high confidence.
2023-10-26 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 对外担保管理制度' which translates to 'Yunnan Bio Valley Pharmaceutical Co., Ltd. External Guarantee Management System'. It details the company's internal policy and procedures regarding external guarantees, including approval processes, risk management, disclosure requirements, and legal responsibilities. The document includes references to board and shareholder meetings for approval but does not present financial statements or audit results. It is a governance-related document outlining internal rules and management practices rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length (6125 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2023-10-26 Chinese
独立董事专门会议工作制度
Governance Information Classification · 95% confidence The document is titled '云南生物谷药业股份有限公司 独立董事专门会议工作制度' which translates to 'Yunnan Biovalley Pharmaceutical Co., Ltd. Independent Directors Special Meeting Work System.' It details the rules and procedures for independent directors' meetings, including meeting convening, voting, and responsibilities. There is no financial data, no mention of financial results, no earnings, no audit reports, no capital changes, or other financial disclosures. It is a governance-related document describing internal rules and procedures for board meetings and independent directors' roles. Therefore, it fits best under Governance Information (CGR). The document length is 2508 characters, which is not a brief announcement but a substantive governance policy document. Hence, the classification is CGR with high confidence.
2023-10-26 Chinese
股东大会制度
Governance Information Classification · 95% confidence The document is a detailed set of rules and procedures governing the conduct of shareholders' meetings (股东大会制度) for a company, including the organization, rights, voting procedures, and responsibilities related to shareholder meetings. It extensively covers the legal framework, meeting convocations, proposal submissions, voting mechanisms, and other governance aspects related to shareholder meetings. There is no indication that this is a report of financial results, audit, or a meeting announcement. Instead, it is a governance document outlining internal rules and procedures for shareholder meetings. Therefore, the document fits best under Governance Information (CGR).
2023-10-26 Chinese
关于拟修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding proposed amendments to the company's Articles of Association (公司章程). It details specific changes to governance provisions, including independent director qualifications, board procedures, and audit committee roles. The document references regulatory rules and laws but does not contain financial statements or audit reports. It is a formal disclosure of governance-related changes requiring shareholder approval. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (8074 characters) and content confirm it is a substantive governance update, not merely an announcement of a report or a brief notice.
2023-10-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.